{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:36:03Z","timestamp":1793126163418,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      In this multicentre, randomised, placebo\u2010controlled and semaglutide\u2010positive\u2010controlled trial, 64 Chinese adults with T2DM were randomly assigned to BGM0504 5\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), 10\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), 15\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912), placebo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) or semaglutide 1\u2009mg (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916). All participants received their assigned dose once weekly for 12\u2009weeks. The primary endpoint was the change in HbA1c from baseline, and secondary endpoints included fasting plasma glucose (FPG), 2\u2010h plasma glucose (2\u2009h PG) and body weight. Safety was assessed through adverse events, laboratory tests and vital signs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At Week 12, the mean changes in HbA1c from baseline were \u22121.72% for the 5\u2009mg dose, \u22121.94% for the 10\u2009mg dose, \u22122.48% for the 15\u2009mg dose, \u22121.43% for 1\u2009mg semaglutide and 0.28% for placebo, with the treatment differences versus placebo (LSM) ranging from \u22121.82% to \u22122.56% (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The proportion of participants achieving HbA1c\u2009&lt;\u20096.5% or &lt;\u20097.0% increased in a dose\u2010dependent manner. BGM0504 also shows a signal for lowering FPG, 2\u2009h PG and body weight (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), with the 15\u2009mg dose showing superior weight reduction to semaglutide. Pharmacokinetics analysis confirmed a linear exposure\u2013response relationship. All doses were well tolerated, with mostly mild adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BGM0504 shows a signal reduction for HbA1c, FPG, 2\u2009h PG and body weight in Chinese adults with T2DM. The 12\u2010week treatment with BGM0504 was safe and well\u2010tolerated, with the 15\u2009mg dose showing the most substantial effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70849","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:04:32Z","timestamp":1780272272000},"page":"7073-7082","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the Safety, Efficacy and Pharmacokinetics of\n                    <scp>BGM0504<\/scp>\n                    in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double\u2010Blind Phase\n                    <scp>II<\/scp>\n                    Trial"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-076X","authenticated-orcid":false,"given":"Ping","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Endocrinology The Third Xiangya Hospital Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangqing","family":"Huang","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Ding","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daosheng","family":"Xie","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Jiang","sequence":"additional","affiliation":[{"name":"The Sweetwood Group LLC  Rockville Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Yuan","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Cao","sequence":"additional","affiliation":[{"name":"Beijing Noahpharm Medical Technology Co. Ltd.  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Noahpharm Medical Technology Co. Ltd.  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Yuan","sequence":"additional","affiliation":[{"name":"BrightGene Bio\u2010Medical Technology Co. Ltd.  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.19"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13759-9"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0442"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-018-1043-z"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_2_9_14_1","unstructured":"Lilly News Release \u201cTreatment With Tirzepatide in Adults With Pre\u2010Diabetes and Obesity or Overweight Resulted in Sustained Weight Loss and Nearly 99% Remained Diabetes\u2010Free at 176\u2009Weeks \u201d2024 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/treatment\u2010tirzepatide\u2010adults\u2010pre\u2010diabetes\u2010and\u2010obesity\u2010or."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30311-0"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66998-8"},{"key":"e_1_2_9_19_1","volume-title":"Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects","author":"World Medical Association","year":"2013"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70849","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:16:36Z","timestamp":1793124996000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/dom.70849"],"URL":"https:\/\/doi.org\/10.1111\/dom.70849","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70849\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v1\/review6","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70849\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"2026-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}